S

Stenocare A/S
CSE:STENO

Watchlist Manager
Stenocare A/S
CSE:STENO
Watchlist
Price: 0.446 DKK 4.45% Market Closed
Market Cap: 17.1m DKK

Relative Value

The Relative Value of one STENO stock under the Base Case scenario is 0.134 DKK. Compared to the current market price of 0.446 DKK, Stenocare A/S is Overvalued by 70%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

STENO Relative Value
Base Case
0.134 DKK
Overvaluation 70%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
20
Median 3Y
24.7
Median 5Y
13.3
Industry
2.5
vs History
vs Industry
Median 3Y
-5
Median 5Y
-7.1
Industry
21.3
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-8
Industry
16.7
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-11.7
Industry
24.7
vs History
4
vs Industry
25
Median 3Y
3.9
Median 5Y
3.5
Industry
2.1
vs History
66
vs Industry
18
Median 3Y
24.8
Median 5Y
12
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.1
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-8.1
Industry
12.8
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-7.1
Industry
16.3
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-8
Industry
14.9
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-7.6
Industry
18.2
vs History
7
vs Industry
58
Median 3Y
3.5
Median 5Y
3.6
Industry
1.9

Multiples Across Competitors

STENO Competitors Multiples
Stenocare A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Stenocare A/S
CSE:STENO
17m DKK 9.2 -0.5 -0.5 -0.5
US
Eli Lilly and Co
NYSE:LLY
711.5B USD 14.5 64.1 34.5 37.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.5B USD 4.2 17 12.5 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 6.8 19.8 13.7 15.7
CH
Roche Holding AG
SIX:ROG
209.8B CHF 3.5 25.4 9.5 11.1
CH
Novartis AG
SIX:NOVN
186.7B CHF 4.3 17.6 10.4 13.9
UK
AstraZeneca PLC
LSE:AZN
164.9B GBP 4.1 28.7 131 197.5
US
Merck & Co Inc
NYSE:MRK
194.1B USD 3 11.1 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
132.7B USD 2.1 16.8 7.3 10.3
P/E Multiple
Earnings Growth PEG
DK
S
Stenocare A/S
CSE:STENO
Average P/E: 25.1
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.1
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.8
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.4
32%
0.8
CH
Novartis AG
SIX:NOVN
17.6
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.7
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.8
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
S
Stenocare A/S
CSE:STENO
Average EV/EBITDA: 433.5
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.5
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
S
Stenocare A/S
CSE:STENO
Average EV/EBIT: 1 867
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.9
CH
Novartis AG
SIX:NOVN
13.9
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.5
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.1
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1